MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia (ALL) Intervention: Drug: Nilotinib Sponsor: Novartis Pharmaceuticals Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Leukemia | Nilotinib | Research | Tasigna